SPRY — ARS Pharmaceuticals, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1671858 ·
Last close
$9.90
Market Cap
$983.10M
52W High
$10.17
52W Low
$7.03
ADV30
1,672,928
Next earnings
2026-08-13
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 22,681,000 | 16,395,000 | -60,145,000 | -60,618,000 | 287,571,000 | 24,321,000 | 226,263,000 |
| Dec 2025 | 28,087,000 | 21,933,000 | -41,465,000 | -41,324,000 | 327,652,000 | 41,317,000 | 213,394,000 |
| Sep 2025 | 32,501,000 | 24,310,000 | -53,192,000 | -51,151,000 | 372,803,000 | 59,557,000 | 225,148,000 |
| Jun 2025 | 15,717,000 | 10,733,000 | -47,614,000 | -44,883,000 | 313,472,000 | 51,540,000 | 121,151,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-175,070,000
Investing CF
$55,495,000
Financing CF
$104,032,000
CapEx
$-641,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.94
As of
2026-06-07
Balance + Analyst (yfinance extras)
Retained Earnings
$-355,221,000
Inventory
$8,817,000
Receivables
$28,662,000
ST Investments
$176,648,000
EBIT TTM
$-189,779,000
Pretax Income TTM
$-198,056,000
Interest Exp TTM
$2,441,000
Analysts
5
Yahoo Snapshot (yfinance, live)
Total Revenue
$98,986,000
EBITDA
$-200,932,000
Free Cash Flow
$-98,275,000
Enterprise Value
$933,467,648
Total Cash
$200,968,992
Total Debt
$171,195,008
Shares Out
99,303,262
Trailing EPS
$-2.00
Book Value
$1.15
ROE
-136.4%
ROA
-41.1%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 84,278,000 | -179,448,000 | -171,298,000 | 327,652,000 | 213,394,000 | — | -170,866,000 |
| Dec 2024 | 89,149,000 | -3,083,000 | 7,998,000 | 351,153,000 | 94,355,000 | — | 13,548,000 |
| Dec 2023 | 30,000 | -67,520,000 | -54,365,000 | 233,188,000 | 2,428,000 | — | -59,266,000 |
| Dec 2022 | 1,316,000 | -35,516,000 | -34,682,000 | 281,435,000 | 8,549,000 | — | -40,078,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.96
Max Pain — expiry 2026-09-18 (volume-derived — Yahoo OI feed degraded)
max pain strike: $10.00 · spot: $9.90 · call volume: 572 · put volume: 10
Expected Move to 2026-09-18:
±$5.15
(52.02%) —
implied range
$4.75 –
$15.05
· ATM straddle on $10.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| CRVS | Corvus Pharmaceuticals, Inc. | $1.01B | $12.00 | — |
| SDGR | Schrodinger, Inc. | $1.02B | $15.53 | — |
| XNCR | Xencor Inc | $947.53M | $12.78 | — |
| JBIO | Jade Biosciences, Inc. | $1.03B | $16.87 | — |
| EVO | Evotec SE | $927.04M | $2.61 | — |
News headlines (Yahoo Finance, 1h cache)
How The Evolving Story For ARS Pharmaceuticals (SPRY) Could Shape Future Valuation
2026-06-09 13:10 · Yahoo
Drew Brees Collaborates with ARS Pharmaceuticals to Raise Awareness About Living Life with Severe Allergies
2026-06-04 12:00 · Yahoo
ARS Pharmaceuticals, Inc. Q1 2026 Earnings Call Summary
2026-05-16 12:30 · Yahoo
ARS Pharmaceuticals Inc (SPRY) Q1 2026 Earnings Call Highlights: Strong Revenue Growth and ...
2026-05-15 23:01 · Yahoo
Sector Update: Healthcare Stocks Decline Late Afternoon
2026-05-15 19:52 · Yahoo
ARS Pharmaceuticals Q1 Earnings Call Highlights
2026-05-15 16:09 · Yahoo
ARS Pharmaceuticals, Inc. (SPRY) Reports Q1 Loss, Beats Revenue Estimates
2026-05-15 11:10 · Yahoo
ARS Pharmaceuticals Reports First Quarter 2026 Financial Results and Corporate Update
2026-05-15 10:00 · Yahoo
Eton Pharmaceuticals, Inc. (ETON) Misses Q1 Earnings Estimates
2026-05-14 21:30 · Yahoo
ARS Pharmaceuticals Strengthens Leadership Team with Appointment of Industry Veteran Donn Casale as President
2026-05-13 12:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.